Phase I study of indibulin in combination with erlotinib in advanced solid tumors.

Trial Profile

Phase I study of indibulin in combination with erlotinib in advanced solid tumors.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Indibulin (Primary) ; Erlotinib
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Jul 2012 Planned end date changed from 1 Jan 2009 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 18 Jul 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jul 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top